Introduction Annual audit of steroid use (longer than 3 months or more than 2 courses in the last year), immunomodulator drugs (IM) and anti-TNF is recommended for inflammatory bowel disease (IBD) services. A local audit was carried out to identify the percentage of IBD patients on long term steroids and to ascertain if the use of IM and anti-TNF therapy was appropriate.
Method 396 patients were identified from the IBD register. Of these 77 were excluded (11 moved away, 10 died, 56 not seen in clinic for >12 months). The medical records of the remaining 319 patients (CD 114, UC 182, IBDu 23) were reviewed and relevant data regarding steroid, IM and anti-TNF use was recorded.
Results 152/319 patients (47%) were on regular 5-ASAs and had not received >2 courses or >3 months of steroids in previous 12 months. 37 (11%) were not on any regular medication. The remaining 130 patients (CD 79, UC 43, IBDu 8) had history of steroid, IM or anti-TNF use. Steroid use of >3 months was evident in 14 patients (10.7%). 13 of the 14 had been tried on IM drugs and 1 had declined. 7 patients (5%) received > 2 courses of steroids in 12 months and all had been tried on IM drugs.
126/319 patients (39%) had been started on Azathioprine or Mercaptopurine, but 26 (20.6%) had discontinued due to intolerance. Use of Methotrexate was low; 10 patients (<1%) were currently on treatment, 5 had declined and 2 had previous intolerance.
The number of patients on anti-TNF was relatively small. 35 patients with CD were treated with anti-TNF. Primary non-response was seen in 4 patients (11%), discontinuation due to side effects occurred in 6 (17%) and deep remission in 3 (8.5%) after more than two years of treatment. Infliximab was stopped in the 3 patients in deep remission in accordance with STORI trial criteria.11 had to restart due to relapse after 4 months, the other 2 remain in remission after 7 months.
Conclusion All 21 patients requiring frequent courses or on long term steroids had been offered IM drugs with 95% starting treatment. Optimisation of IM was attempted in all patients with dosing based on weight and TPMT levels. Our strategy has recently changed and we now use 6 TGN levels for dose optimisation with review at the monthly Virtual Biologics and Immunomodulator clinic.
Disclosure of interest None Declared.
Louis E, Mary J-Y, Vernier-Massouille G. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after Infliximab therapy is stopped. Gastroenterology 2012;142:63–70
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.